The main objectives of this study were to (i) generate GEP of 89 immunotherapy-naïve BRAF-CRCs, (87% of which were advanced CRCs) using the PanCancer IO 360 gene expression panel and the NanoString nCounter platform; (ii) to evaluate the association between MMR status/CD8+ TIL infiltrate and immune-related gene signatures of BRAF-CRCs; (iii) to explore the distribution of Tumor Inflammation Signature (TIS) scores within BRAF-CRCs; (iv) to assess the TIS score’s prognostic value. This evidence concerns the gene CD8A and neoplasm.